Voltar à classificação

Nordson Corporation (NDSN)

Valor Justo
IndustrialsSpecialty Industrial MachineryUnited States

Fundamental

71

Preço

$327.85

Capitalização de Mercado

$18.01B

Parte 1 · Quanto vale a empresa

Visão Geral

Nordson makes precision dispensing equipment: machines that apply exact, controlled amounts of adhesives, coatings, sealants and other fluids inside a factory line, plus components used in medical devices and semiconductor manufacturing. Its products are typically a small line item inside a much larger production process — a diaper plant's glue applicator, a chip packaging step, a catheter's plastic tubing — but a failure or imprecision there can shut the whole line down.

Como gera receita

Revenue comes mostly from selling dispensing systems and components once, plus recurring sales of spare parts, nozzles and service that keep those systems running precisely over years of use. Because customers integrate Nordson's equipment into a validated production process, replacing it later requires re-qualifying the whole line, which supports steady repeat business rather than one-off equipment sales.

Receita por segmento

Industrial Precision Solutions48%

Adhesive, coating and sealant dispensing systems sold into packaging, general industrial and consumer goods production lines.

Medical and Fluid Solutions30%

Components and precision fluid-management systems used in medical devices such as catheters, plus fluid dispensing for other industries.

Advanced Technology Solutions22%

Equipment used in semiconductor and electronics manufacturing, including chip packaging and testing steps.

Vantagem competitiva

Custos de mudança · Estreita

Once a customer validates a production line around Nordson's dispensing equipment — calibrated to exact fluid volumes and tolerances, sometimes under regulatory approval as in medical devices — swapping to a competitor means re-validating the whole line, a costly and slow process manufacturers avoid unless something is badly wrong. That keeps replacement parts and service revenue sticky even where the original equipment sale was competitive.

O que impulsiona a procura

Moderadamente cíclico

Demand splits between steadier end markets — packaging, medical devices, consumer nondurables — and more cyclical ones like semiconductor and electronics capital spending, which swings with chip industry investment cycles. The mix of the three segments smooths some of that cyclicality but does not remove it, particularly in the Advanced Technology segment.

Principais riscos

  • Cyclicality in semiconductor capital spending — The Advanced Technology Solutions segment depends on chip makers' capital equipment budgets, which are historically volatile and can swing sharply between shortage and oversupply periods.
  • Acquisition integration risk — Nordson has grown its segments partly through acquisitions; integrating acquired businesses' operations, systems and customer relationships carries execution risk and can strain expected returns.
  • Customer capital spending decisions — Equipment sales depend on customers deciding to build or upgrade production lines, decisions that can be postponed in an uncertain economic environment even when replacement parts demand continues.
  • International operations and currency exposure — A significant share of sales and manufacturing occurs outside the United States, exposing results to currency translation and to economic and trade conditions in those markets.

Os argumentos a favor

Buyers argue that Nordson's equipment gets embedded in validated production lines across three diversified end markets, that recurring parts and service revenue smooths the cycle, and that record fiscal 2025 results show the model compounding through both steadier and more cyclical segments at once.

Os argumentos contra

Sellers fear that the Advanced Technology segment remains exposed to a genuinely volatile semiconductor capital-spending cycle, that growth built partly through acquisitions carries integration risk that can disappoint, and that a broader industrial slowdown would delay the equipment upgrades that drive the larger, steadier segments too.

Written by the editors, published on 18 de agosto de 2026

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balanço & Liquidez

Receita

$2.98B

Últimos 12 meses (até 31/07/2026)

Resultado Líquido

$555M

Últimos 12 meses (até 31/07/2026)

Fluxo de Caixa Livre

$661M

Capital Próprio Total

$3.04B

Passivo Total

$2.87B

Rácio de Liquidez

1.82

Cobertura de Juros

8.83

Dívida/EBITDA

2.30

Resultados Por Ação

Receita & Resultado Líquido

Fluxo de Caixa Livre

Decomposição dos Resultados

Demonstração histórica

Margens ao longo do tempo

A dívida ao longo do tempo

Quanto pesa a dívida

Grelha do crescimento

Crescimento — Receitas

Estimativa de Valor Justo

Caso geralJustamente Valorizada

Valor Justo

$294.61

Preço Atual

$327.85

Margem de Segurança

-11.3%

Intervalo de Valor Justo

$226.16 - $363.07

Dispersão entre os métodos de avaliação utilizados, não um intervalo de confiança calibrado estatisticamente.

Métodos de Estimativa

Preço-alvo dos analistas:$349.71
Fluxo de caixa descontado (DCF):$318.09
Multiplicador de lucros (P/E):$246.87
Fórmula de crescimento de Graham:$331.94
Valor da capacidade de gerar lucro (EPV):$109.69
P/B justificado:$123.56
Desconto de dividendos (Gordon):$55.01
P/FFO, fundos de operações:$161.94
Lucros de meio de ciclo:$260.50
Multiplicador sobre as receitas:$151.25
Consenso dos Analistas:Comprar (9B / 6H / 0S)
Última Surpresa de Resultados:+2.66%

Métricas de Avaliação

Rácio P/E

33.22

ROE

15.9%

Rácio P/B

5.59

P/FCF

25.22

Margem Bruta

55.3%

ROIC

12.1%

Radar de Rentabilidade

Criação de Valor (Vantagem Competitiva)

ROIC

12.1%

WACC

9.5%

ROIC − WACC

+2.6 pp

O ROIC supera o custo do capital — a empresa está a criar valor para os acionistas.

Critérios de Análise Fundamental

Aprovado (21)

  • EPS shows upward trend
  • EPS CAGR 5.49%
  • Price CAGR 11.11%
  • ROIC 12.1%
  • Gross Margin 55.3%
  • P/FCF 25.22
  • Debt/Equity ratio
  • Operating Margin 26.9%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 17.6%
  • Revenue Growth 5Y 5.7%
  • Analyst Consensus 60% Buy
  • Earnings Quality (OCF/NI) 1.39
  • Share Dilution -1.2%
  • Net Margin Trend 18.6% vs 16.3%
  • Piotroski F-Score 7/9

Reprovado (6)

  • P/B Ratio 5.59
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Earnings Surprise avg 0.3%
  • PEG Ratio 2.18

Indisponível (1)

  • Dividend Payout NaN%

Piotroski F-Score

7/9

Saúde financeira sólida

score
criteria

Qualidade dos Resultados

1.39

Alta qualidade: resultados respaldados por caixa

Diluição de Ações

-1.2%

A recomprar ações. Favorável ao acionista

Participações institucionais

Governação

Equipa Executiva

NomeCargoIdade
Mr. Sundaram NagarajanPresident, CEO & Director62
Mr. Daniel R. HopgoodExecutive VP & CFO52
Ms. Jennifer L. McDonough J.D.Executive VP, General Counsel & Corporate Secretary53
Mr. Joseph P. KelleyExecutive VP of Industrial Precision Solutions Leader52
Mr. Joseph M. RutledgeVP & Chief Accounting Officer45
Ms. Lara L. MahoneyVice President of Investor Relations & Corporate Communications-
Katie ColacarroVice President of Corporate Development-
Ms. Sarah SiddiquiExecutive VP & Chief Human Resources Officer47
Mr. Justin HallExecutive Vice President of Medical & Fluid Solutions46
Mr. Matthew MatejkaSenior Director of Investor Relations-

Risco de Auditoria

8

Risco do Conselho

3

Risco de Remuneração

6

Risco dos Direitos dos Acionistas

10

Parte 2 · O preço e o momento de entrar

Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.

Documentos

  • Relatório anual (10-K)

    Uma visão anual do negócio, dos resultados financeiros e dos riscos da empresa.

    Arquivado em 2025-12-17

    Ver documento
  • Relatório trimestral (10-Q)

    Uma atualização sobre o desempenho financeiro dos últimos três meses.

    Arquivado em 2026-08-20

    Ver documento
  • Relatório de fato relevante (8-K)

    Um aviso sobre um fato relevante, como uma mudança na liderança ou um grande anúncio.

    Arquivado em 2026-08-19

    Ver documento

via SEC EDGAR

Histórico de Resultados

via SEC EDGAR

Latest News

Recent headlines for NDSN, sourced from Markets Gazette.

  • 8/21/2026POSITIVE
    Thursday’s Activity, 4 Possible Friday Plays

    Nordson Corporation (NDSN) was highlighted as a potential multi-bagger opportunity in Thursday's trading session, with the NDSN Weekly $310-320 call options showing significant upside potential. The article suggests that the stock has delivered strong performance, aligning with the firm's successful track record of identifying profitable trading plays. Investors who followed this recommendation may have seen substantial gains, indicating positive momentum for the company's stock.

via Markets Gazette